Winona Tse, MD Email Winona Tse
- ASSOCIATE PROFESSOR | Neurology
- Chinese (Cantonese)
- Chinese (Mandarin)
- Hospital Affiliation
- The Mount Sinai Hospital
- Mount Sinai Movement Disorders Center 212-241-5607212-241-5607
Dr. Tse earned a Bachelor of Arts degree in Biology from the Brown University Program in Liberal Medical Education in 1991, and then graduated with an M.D. degree from SUNY Stony Brook Medical School in 1995. Dr. Tse completed a neurology residency at Mount Sinai Medical Center in 1999, and in the final year served as a Chief Resident. She then completed a fellowship in electromyography at the New York-Cornell Presbyterian Medical Center. She worked at Maimonides Hospital in Brooklyn from 2000 to 2002, where she saw a variety of movement disorders.
Currently, as an Assistant Professor of Neurology in the Mount Sinai Movement Disorders Center, Dr. Tse sees patients with Parkinson's disease, tremor disorders, dystonia and other movement disorders.
Dr. Tse is a diplomate of the American Board of Psychiatry and Neurology, and a diplomate of the American Academy of Electrodiagnostic Medicine.
Am Board of Electrodiagnostic Medicine
Neurology, American Board of Psychiatry and Neurology
- Benign Essential Tremor
- Botulinum Toxin Injections
- Cervical Dystonia
- Limb Dystonia
- Multiple System Atrophy
- Parkinson's Disease
- Post-Stroke Spasticity
- Restless Legs Syndrome
- Shy-Drager Syndrome
- Tardive Dyskinesia
- Tic Disorder
- Writers' Cramp
MD, S.U.N.Y., Stony Brook Sch. of Med
Internship, Internal Medicine
Mount Sinai Hospital
Mount Sinai Hospital
Fellowship, Neuromuscular Dis
Chinese (Cantonese), Chinese (Mandarin), English, Spanish
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BMS-986168 in Participants with Progressive Supranuclear Palsy
The purpose of this study is to evaluate the safety, effectiveness and tolerability (level of side effects) of an experimental drug called BMS-986168, being developed for the treatment of Progressive Supranuclear Palsy (PSP). BMS-986168 is not approved by the United States Food a...
A Phase IIIB, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Dysport Using 2 mf Dilution in Adults with Cervical Dystonia
The purpose of this research study is to evaluate the safety and effectiveness of a botulinum toxin for treating cervical dystonia. This study will look at botulinum toxin as a 2 milliliter (about ½ teaspoon) injection compared to a placebo. The Parkinson and Movement Disorder Ce...
A Multicenter, Multinational, Double-blind, Placebo-controlled, 3-arm, Phase 4 Study to Evaluate the Efficacy of Rotigotine on Parkinson’s Disease-Associated Apathy, Motor Symptoms, and Mood ("BRIGHT")
Patients with Parkinson's disease have low levels of dopamine in the brain. Rotigotine, the drug being studied, acts like dopamine and may relieve some symptoms of Parkinson's disease. It is given in the form of a patch worn 24 hours on the skin. The primary purpose of this study...
To Assess Sustained EffecTs Of Droxidopa Therapy On Patients With Symptomatic Neurogenic Orthostatic Hypotension
The purpose of this research study is to evaluate the durability of the effectiveness and safety of a study drug called droxidopa (also known by the trade name NORTHERA®) in people with symptomatic neurogenic orthostatic hypotension (NOH). Droxidopa (NORTHERA®) has been ...
A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients with Parkinson’s Disease Experiencing End of Dose "Wearing-Off"
The purpose of this study is to evaluate the safety and effectiveness of an experimental drug called tozadenant as a possible treatment of the symptoms of Parkinson's disease.The most widely used medication for the treatment of Parkinson's disease is levodopa (L-dopa). However, L...
A Double-Blind, Cross-Over, Placebo-Controlled Efficacy and Tolerability Study of Perampanel for Essential Tremor
The purpose of this study is to learn whether a drug called Perampanel can help with essential tremor and is safe for people to take. Essential Tremor is a condition in which the hands shake when they are being used to hold things. Other parts of the body such as the head and voi...
Open label long term tolerability and Efficacy of APL-1302677 (apomorphine) in Levodoa responsive patients with PD having "OFF episodes"
Parkinson's disease affects about 1 million people in the United States. Up to 50% of those affected experience daily changes in performing motor activities, called "OFF" episodes. These include periods of time where their medication wears off before the next dose and their Parki...
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson’s Disease Patients With Motor Response Fluctuations (OFF Phenomena)
This study is evaluating an investigational, inhaled form of levodopa (CVT-301) in patients with Parkinson's disease who experience OFF episodes (periods when they feel their oral Parkinson's medication is no longer working). To qualify patients with Parkinson's disease should ex...
Koller WC, Tse W. Unmet medical needs in Parkinson's disease. Neurology 2004 Jan 13; 62(1 Suppl 1): S1-S8.
Tse W, Koller W, Olanow CW. Restless legs syndrome. In: Chaudhuri R, Odin P, Olanow CW, editors. Restless Legs Syndrome. New York, Taylor and Francis; 2004.
Halbig TD, Tse W, Olanow CW. Neuroprotective agents in Parkinson's disease: clinical evidence and caveats. Neurol Clin 2004 Oct; 22(3 Suppl): S1-S17.
Germano IM, Gracies JM, Weisz DJ, Tse W, Koller WC, Olanow CW. Unilateral stimulation of the subthalamic nucleus in Parkinson disease: a double-blind 12-month evaluation study. J Neurosurg 2004 Jul; 101(1): 36-42.
Tse W, Liu Y, Barthlen GM, Halbig TD, Tolgyesi SV, Gracies JM, Olanow CW, Koller WC. Clinical usefulness of the Parkinson's disease sleep scale. Parkinsonism Relat Disord 2005 Aug; 11(5): 317-21.
Hälbig TD, Assuras S, Creighton J, Borod JC, Tse W, Frisina PG, Voustianiouk A, Gracies JM, Olanow CW. Differential role of dopamine in emotional attention and memory: evidence from Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society 2011 Aug; 26(9).
Hälbig TD, Creighton J, Assuras S, Borod JC, Tse W, Gracies JM, Foldi NS, Kaufmann H, Olanow CW, Voustianiouk A. Preserved emotional modulation of motor response time despite psychomotor slowing in young-old adults. The International journal of neuroscience 2011 Aug; 121(8).
Hälbig TD, Borod JC, Frisina PG, Tse W, Voustianiouk A, Olanow CW, Gracies JM. Emotional processing affects movement speed. Journal of neural transmission (Vienna, Austria : 1996) 2011 Sep; 118(9).
Tse W, Hälbig TD. Skin picking in Parkinson's disease: a behavioral side-effect of dopaminergic treatment?. Psychiatry and clinical neurosciences 2010 Apr; 64(2).
Frisina PG, Tse W, Hälbig TD, Libow LS. The pattern of cognitive-functional decline in elderly essential tremor patients: an exploratory-comparative study with Parkinson's and Alzheimer's disease patients. Journal of the American Medical Directors Association 2009 May; 10(4).
Tse W, Frisina PG, Hälbig TD, Gracies JM, Liang L, Tarshish C, Lesser G, Neufeld R, Koller WC, Libow LS. The effects of withdrawal of dopaminergic medication in nursing home patients with advanced parkinsonism. Journal of the American Medical Directors Association 2008 Nov; 9(9).
Gracies JM, Tse W, Lugassy M, Frank J. Physical therapy in Parkinson's disease. Handbook of clinical neurology 2007; 84.
Tse W, Libow LS, Neufeld R, Lesser G, Frank J, Dolan S, Tarshish C, Gracies JM, Olanow CW, Koller WC, Hälbig TD. Prevalence of movement disorders in an elderly nursing home population. Archives of gerontology and geriatrics 2008; 46(3).
Tse W. Abnormal Movements and Incoordination. In: Sealfon S, Motiwala R, Stacy C, editors. Mount Sinai Expert Guides: Neurology. New York, John Wiley & Sons;.
Tse W. Parkinson's disease and essential tremor. In: Chai E, Morris J, Goldhirsch SL, Meier DE, editors. Geriatric Palliative Care. Oxford University Press;.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Tse has not yet completed reporting of Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.